Nyxoah S.A.

NASDAQ:NYXH

Medical - Instruments & Supplies

Healthcare
$0.86 +1.25%

+$0.02 today

Market cap
$87.89M
Beta
0.89
P/E (TTM)
-0.7
EPS (TTM)
-$1.99
52W Low $1.26High $8.59

Volume 0.17M

Average 0.22M

NYXH Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Nyxoah S.A.NASDAQ: NYXH

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization growth accelerates

Q1 FY2026 depreciation & amortization of €1.72M rose 122.5% year over year, ahead of the +88.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 15.2% from the prior quarter. Over 3 fiscal years it compounded at +32.4% a year.

Context

  • Depreciation & amortization amounted to 44.7% of revenue in FY2025, down 15.4 pp from a year earlier.
  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +122.5% holds above the trailing-twelve-month pace of +88.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
€1.72M+15.2% QoQ
Last fiscal yearDec 2025
€4.48M+64.9% YoY
LTMMar 2026
€5.43M+88.5% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+122.5%——
1 year+64.9%——
3-year CAGR+32.4%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

EUR · from the cash flow

Latest · FY2025
4.48M EUR
Year-over-year change
+64.9%
4-year CAGR
+28.1%

Depreciation & Amortization vs competitors

How NYXH compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +88.5% is the highest of 9, against a peer median of -4.0%.
  • Depreciation & amortization amounts to 33.3% of revenue for NYXH, versus a peer median of 4.7%.
NYXH Competitors
Depreciation & Amortization for NYXH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OABIOmniAb, Inc.LTM Mar 2026$23.65M USD+1.1%+6.0%81.8%
OSUROraSure Technologies, Inc.LTM Mar 2026$9.86M USD-9.2%-91.3%8.7%
NYXHNyxoah S.A.LTM Mar 2026€5.43M EUR+88.5%+32.4%33.3%
PREPrenetics Global LimitedLTM Mar 2026$3.97M USD—-20.6%3.5%
CATXPerspective Therapeutics, Inc.LTM Mar 2026$3.65M USD+35.4%+111.4%589.8%
STIMNeuronetics, Inc.LTM Mar 2026$3.3M USD+36.1%+28.1%2.2%
UTMDUtah Medical Products, Inc.LTM Mar 2026$2.22M USD-23.2%-24.8%5.9%
IVVDInvivyd, Inc.LTM Mar 2026$1.88M USD-43.4%+65.8%3.4%
KRMDKORU Medical Systems, Inc.LTM Mar 2026$790.67K USD-9.6%+11.3%1.8%
TARAProtara Therapeutics, Inc.LTM Mar 2026$369K USD+11.1%+13.4%—
Peer median (excluding NYXH) —-4.0%+11.3%4.7%

Competitors are the stored peer set for NYXH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(24.64M)(30.06M)(44.66M)(56.43M)(90.05M)
Depreciation & Amortization1.66M1.93M2.36M2.72M4.48M
Deferred Income Tax00000
Stock-Based Compensation1.27M2.7M2.61M3.97M0
Change in Working Capital(1.14M)86K(3.49M)2.96M5.37M
Accounts Receivables(2.52M)7K(1.54M)(751K)(2.14M)
Inventory(291K)(536K)(2.43M)(1.4M)55.98K
Accounts Payables00007.45M
Other Working Capital1.67M615K479K5.11M0
Other Non-Cash Items(2.49M)(3.42M)(1.6M)(2.44M)12.7M
Operating Cash Flow(25.34M)(28.76M)(44.78M)(49.23M)(67.5M)
Capital Expenditures(11.82M)(16.35M)(10.96M)(6.07M)(804.7K)
Acquisitions (Net)00003K
Purchases of Investments0(102.62M)(80.02M)(97.83M)(42.03M)
Sales of Investments028.91M120.68M85.31M71.97M
Other Investing Activities(10.35M)(15.35M)(6.15M)(2.64M)0
Investing Cash Flow(11.82M)(89.95M)32.01M(16.33M)26.17M
Debt Repayment(863K)(1.07M)(1.24M)8.48M21.19M
Common Stock Issued77.73M255K18.34M69.72M20.86M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(393K)(167K)(243K)(758K)(3.26M)
Financing Cash Flow76.47M(983K)16.86M77.44M38.79M
Effect of Forex Changes3.89M2.06M(369K)688K2.41M
Net Change in Cash43.21M(117.62M)3.72M12.58M(130.69K)
Free Cash Flow(37.15M)(45.11M)(55.74M)(55.3M)(68.3M)

Nyxoah S.A.

NASDAQ:NYXH

Intrinsic Alpha fair value

Locked

Current Price

$0.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.